Biotech News

Pyxis Oncology to Participate in Upcoming Investor Conferences

Pyxis Oncology (PYXS)Pyxis OncologyCompany update

Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Tom Civik, Chief Executive Officer and Chairman of Pyxis Oncology, will participate in fireside chats at two upcoming conferences.

Related news

Pyxis Oncology

Tumor-Microenvironment ADC Company Pyxis Oncology develops antibody-drug conjugates for difficult-to-treat cancers, with a strategy that targets structural components of the tumor microenvironment. MICVO Micvotabart pelidotin, or MICVO, targets extradomain-B fibronectin, a non-cellular component enriched in tumor tissue. This approach is...

Recent company news

Stock data

Close
1.68 USD
Market cap
108.34M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States